Schedule 13D ownership disclosure
Gemini Therapeutics, Inc. /DE
Security class unavailable · CUSIP: 36870G105
Event date: 2022-08-09
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 4,870,250
- Percent of class
- 11.2600%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950127-22-000039
- Form type
- SC 13D
- Filer
- FS Development Holdings, LLC
- CIK
- CIK 1820810
- Filed
- Aug 12, 2022
- Reporting period
- Aug 09, 2022
- Description
- Schedule 13D beneficial ownership